toujeo
Sanofi secures expanded European approval for Toujeo in type 1 diabetes
January 10, 2020Medical Communications, Sales and Marketing EU, Sanofi, pharma, toujeo
Sanofi has revealed that the European Commission has expanded the existing label for Toujeo (insulin glargine 300 units/mL) to include …
Promising Phase 3 data for Sanofi’s Toujeo secures CHMP recommendation of label expansion in type 1 diabetes
November 4, 2019Research and Development, Sales and Marketing EU, Sanofi, Type 1 diabetes, diabetes, pharma, toujeo
Sanofi took the opportunity at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference in Boston, Massachusetts to …
Sanofi’s Toujeo proves non-inferior to insulin degludec in type 2 diabetes
June 26, 2018Manufacturing and Production, Research and Development, Sales and Marketing American Diabetes Association, Sanofi, diabetes, insulin glargine, pharma, toujeo, type 2 diabetes
Sanofi took the opportunity at the American Diabetes Association (ADA) 78th Scientific Sessions in Florida to unveil new data on …
Sanofi launches new insulin Toujeo in the UK
August 4, 2015Manufacturing and Production, Sales and Marketing Lantus, Sanofi, biosimilars, diabetes, hypoglycaemia, insulin, toujeo
Sanofi’s new insulin Toujeo is now available for clinicians to prescribe in the UK. The French firm is looking to …
Sanofi’s Toujeo approved in Japan
July 3, 2015Manufacturing and Production, Sales and Marketing Japan, Lantus Lantus XR, Sanofi, diabetes, toujeo, type diabetes
The Ministry of Health, Labor and Welfare in Japan has given Sanofi a marketing authorisation for the diabetes drug the …
Sanofi rules out Toujeo discount in diabetes
April 14, 2015Sales and Marketing 100 U/mL, Boehringer, Lantus, insulin glargine [rDNA origin] injection, lilly, toujeo
Sanofi has revealed that it will not discount its new insulin Toujeo more than its current blockbuster Lantus, despite lacking …
Type 1 diabetes market value to double by 2023
March 19, 2015Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1
The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …
Latest content
